Voriconazole: Difference between revisions

From IDWiki
No edit summary
(: added a few)
Line 26: Line 26:
 
** Floaters etc that may improve with time
 
** Floaters etc that may improve with time
 
** Visual hallucinations
 
** Visual hallucinations
  +
** Colour vision loss
  +
* Photosensitivity
 
* Hepatotoxicity
 
* Hepatotoxicity
 
* QTc prolongation
 
* QTc prolongation

Revision as of 11:05, 21 November 2019

Therapeutic Drug Monitoring

  • Measure trough within 7 days of starting, and at regular intervals or following dose adjustment
  • Target trough > 1 mg/L for prophylaxis and treatment
Trough (mcg/mL) Recommendation
0.0 to 0.6 Increase dose by 100 mg and recheck trough on day 5 of new regimen
0.7 to 0.9 Increase dose by 50 mg and recheck trough on day 5 of new regimen
1.0 to 4.0 At target, no dose adjustment needed
4.1 to 5.5 Decrease dose by 50 mg and recheck trough on day 5 of new regimen
5.6 to 7.9 Hold dose. Follow daily trough levels, then restart when trough is ≤2.5 at a dose decreased by 100 mg. Recheck trough on day 5 of new regimen.
≥8.0 Hold dose. Follow daily trough levels, then restart when trough is ≤2.5 at a dose decreased by 50%. Recheck trough level on day 5 of new regimen.

Adverse Effects

  • Visual
    • Floaters etc that may improve with time
    • Visual hallucinations
    • Colour vision loss
  • Photosensitivity
  • Hepatotoxicity
  • QTc prolongation

Further Reading

References

  1. ^  Romeo-Gabriel Mihăilă. Voriconazole and the liver. World Journal of Hepatology. 2015;7(13):1828. doi:10.4254/wjh.v7.i14.1828.